IL315207A - Antibody-conjugates for targeting of tumours expressing trop-2 - Google Patents
Antibody-conjugates for targeting of tumours expressing trop-2Info
- Publication number
- IL315207A IL315207A IL315207A IL31520724A IL315207A IL 315207 A IL315207 A IL 315207A IL 315207 A IL315207 A IL 315207A IL 31520724 A IL31520724 A IL 31520724A IL 315207 A IL315207 A IL 315207A
- Authority
- IL
- Israel
- Prior art keywords
- expressing tumors
- antibody pairs
- targeting trop
- trop
- targeting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163943 | 2022-03-23 | ||
| PCT/EP2023/057561 WO2023180485A1 (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing trop-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315207A true IL315207A (en) | 2024-10-01 |
Family
ID=81308125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315207A IL315207A (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing trop-2 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250090679A1 (https=) |
| EP (1) | EP4496594A1 (https=) |
| JP (1) | JP2025510700A (https=) |
| KR (1) | KR20250024743A (https=) |
| CN (1) | CN119212731A (https=) |
| AU (1) | AU2023241225A1 (https=) |
| CA (1) | CA3253220A1 (https=) |
| IL (1) | IL315207A (https=) |
| MX (1) | MX2024011520A (https=) |
| WO (1) | WO2023180485A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| EP0856054B1 (en) | 1995-10-19 | 2004-04-28 | Bristol-Myers Squibb Company | Monoclonal antibody br110 and uses thereof |
| US9745380B2 (en) | 2002-03-01 | 2017-08-29 | Immunomedics, Inc. | RS7 antibodies |
| CA2478047C (en) | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| DK3438131T3 (da) | 2006-02-10 | 2022-04-11 | Life Technologies Corp | Oligosaccharidmodifikation og mærkning af proteiner |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| CA2750038C (en) | 2009-02-05 | 2016-10-04 | Oncoxx S.R.L. | Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| TWI495644B (zh) | 2011-11-11 | 2015-08-11 | Rinat Neuroscience Corp | 營養層細胞表面抗原（Ｔｒｏｐ－２）之專一性抗體類及彼等之用途 |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| EP4148138A1 (en) | 2014-08-04 | 2023-03-15 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| CN107106701B (zh) | 2014-10-03 | 2020-11-06 | 西纳福克斯股份有限公司 | 磺酰胺接头、其缀合物及制备方法 |
| WO2016170186A1 (en) | 2015-04-23 | 2016-10-27 | Synaffix B.V. | PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CN113260384A (zh) * | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| MX2021011812A (es) | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| KR20230021018A (ko) | 2020-06-05 | 2023-02-13 | 재단법인 생물기술개발중심 | 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도 |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁（苏州）生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| KR20230015301A (ko) | 2021-07-19 | 2023-01-31 | 맙플렉스 인터내셔널 컴퍼니 리미티드 | 2성분 독소가 부하된 항체-약물 접합체 및 그의 용도 |
-
2023
- 2023-03-23 CA CA3253220A patent/CA3253220A1/en active Pending
- 2023-03-23 EP EP23714682.4A patent/EP4496594A1/en active Pending
- 2023-03-23 CN CN202380028866.0A patent/CN119212731A/zh active Pending
- 2023-03-23 IL IL315207A patent/IL315207A/en unknown
- 2023-03-23 WO PCT/EP2023/057561 patent/WO2023180485A1/en not_active Ceased
- 2023-03-23 AU AU2023241225A patent/AU2023241225A1/en active Pending
- 2023-03-23 JP JP2024556005A patent/JP2025510700A/ja active Pending
- 2023-03-23 KR KR1020247034725A patent/KR20250024743A/ko active Pending
-
2024
- 2024-09-19 MX MX2024011520A patent/MX2024011520A/es unknown
- 2024-09-20 US US18/892,270 patent/US20250090679A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023180485A1 (en) | 2023-09-28 |
| CA3253220A1 (en) | 2023-09-28 |
| US20250090679A1 (en) | 2025-03-20 |
| KR20250024743A (ko) | 2025-02-19 |
| CN119212731A (zh) | 2024-12-27 |
| MX2024011520A (es) | 2025-01-09 |
| EP4496594A1 (en) | 2025-01-29 |
| AU2023241225A1 (en) | 2024-08-29 |
| JP2025510700A (ja) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL312972A (en) | Pharmaceutical composition comprising a quinazoline compound | |
| IL315205A (en) | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen | |
| IL315000A (en) | Engineered cd47 proteins and uses thereof | |
| IL314993A (en) | Anti-cd28 x anti-psma antibodies | |
| IL312989A (en) | Il15/il15rα heterodimeric fc-fusion proteins | |
| IL314996A (en) | Compositions and methods for stimulating natural killer cells | |
| IL315207A (en) | Antibody-conjugates for targeting of tumours expressing trop-2 | |
| NO20083127L (no) | Fremgangsmater og preparater for malretting av polyubiquitin | |
| WO2019241430A3 (en) | Antibody-oligonucleotide conjugates | |
| MX2024014691A (es) | Enlazadores de conjugacion mejorados | |
| WO2010108125A3 (en) | Psma-targeting compounds and uses thereof | |
| JP2023100643A5 (https=) | ||
| WO2018109170A3 (en) | Il-11ra antibodies | |
| NO20083147L (no) | Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse | |
| JP2022116141A5 (https=) | ||
| WO2021055577A3 (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use | |
| WO2018169901A8 (en) | Synthetic promoters | |
| EP4054648A4 (en) | ANTIBODY DRUG CONJUGATES DIRECTED AGAINST CLAUDIN 18.2 | |
| MX2022007960A (es) | Nuevos anticuerpos anti-fgfr2b. | |
| EP4263509A4 (en) | RADIOACTIVELY LABELLED COMPOUNDS FOR TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | |
| IL320615A (en) | PSMA-targeting linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same materials | |
| IL315873A (en) | Analysis of genomic word frameworks on genomic methylation data | |
| NO20074476L (no) | Ikke-vandige enkeltfasede vehikler og formuleringer som anvender slike vehikler | |
| WO2023147588A3 (en) | Enhanced-affinity anti-ecm nanobody-cytokine fusions and their applications | |
| JP2019195314A5 (https=) |